Sort by
Refine Your Search
-
Listed
-
Employer
- Delft University of Technology (TU Delft)
- University of Amsterdam (UvA)
- Delft University of Technology (TU Delft); yesterday published
- Eindhoven University of Technology (TU/e)
- University of Amsterdam (UvA); yesterday published
- Utrecht University
- Wageningen University & Research
- Amsterdam UMC
- Amsterdam UMC; Amsterdam
- Amsterdam UMC; 27 Sep ’25 published
- Amsterdam UMC; Published today
- Amsterdam UMC; Published yesterday
- Amsterdam UMC; today published
- Delft University of Technology (TU Delft); Delft
- Delft University of Technology (TU Delft); 26 Sep ’25 published
- Delft University of Technology (TU Delft); Published 21 Nov ’25
- Eindhoven University of Technology (TU/e); Eindhoven
- Eindhoven University of Technology (TU/e); yesterday published
- Erasmus MC (University Medical Center Rotterdam)
- Erasmus MC (University Medical Center Rotterdam); today published
- European Space Agency
- Leiden University Medical Center (LUMC)
- Maastricht University (UM)
- Maastricht University (UM); yesterday published
- Radboud University
- Radboud University Medical Center (Radboudumc)
- University Medical Center Utrecht (UMC Utrecht); today published
- University of Amsterdam (UvA); 26 Sep ’25 published
- University of Amsterdam (UvA); Published today
- University of Amsterdam (UvA); Published yesterday
- University of Twente
- University of Twente (UT)
- University of Twente (UT); Published today
- University of Twente (UT); today published
- Wageningen University and Research Center
- 25 more »
- « less
-
Field
-
of induced pluripotent stem cells (iPSC) of PD(D)/DLB patients to identify molecular profiles and drug targets. We will collect skin biopsies from PD patients of whom brain pathological confirmation is
-
patient. Research in the department focuses on novel, individualized treatment strategies in the field of targeted agents and immunotherapy, either alone or in combination with conventional chemotherapy
-
bioluminescent imaging with cutting-edge organ-on-chip models, the project aspires to enhance understanding of OA pathology and facilitate the development of targeted therapies. This approach not only aims
-
) multi-omics analysis for the identification of therapeutic targets (biomarkers or druggable targets). The candidate will also develop and implement AI-driven tools to predict disease prognosis and
-
optimization, particularly in the context of the Energy Transition. Transitioning to a power system heavily reliant on weather-dependent renewable energy to achieve environmental targets introduces a critical
-
/hybrid implementations of AI algorithms, novel quantum computing algorithms, etc.); conduct theoretical studies to identify target EO use cases that could benefit from (hybrid) quantum computing solutions
-
Postdoc in Extracellular Vesicles as Mediators of Gut-Microbiome Interactions in Parkinson's Disease
disease. Using unique bacterial isolates from colonic, ileal, and fecal samples of PD patients and matched controls, you will explore EV-microbiome interactions, focusing on bacterial gene targets, growth
-
. However, it must become more efficient and sustainable, while achieving higher purity and recovery rates to meet EU regulatory targets. This project is part of the CRM Lion project, which is part of
-
transcranial magnetic stimulation (TMS) towards the development of TUS protocols for modulating subcortical targets in humans. The goal is to leverage ’lessons learned’ from TMS/TMS-EEG/fMRI research such as
-
variable composition of industrial Li-ion waste streams. However, it must become more efficient and sustainable, while achieving higher purity and recovery rates to meet EU regulatory targets. This project